Latest Tg Therapeutics (TGTX) Headlines
TG Therapeutics, Inc. Announces $18.1 Million Underwritten Sale of Common Stock to a Single Institutional Investor
GlobeNewswire - 1 hr 39 mins ago
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced it has priced an underwritten sale of 2,702,809 shares of its common stock at $6.71 per share, the closing price on March 11, 2014, to JP Morgan Asset Management's Global Healthcare Fund. Gross proceeds from the sale are expected to be approximately $18.1 million. TG Therapeutics intends to use the proceeds from the offering to fund the clinical development of TG-1101 and TGR-1202 and other general corporate purposes. The offering is expected to close on or about March 17, 2014, subject to customary closing conditions.
TG Therapeutics, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Mar 10, 9:01AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 26 Annual ROTH Conference being held at the Ritz Carlton Hotel in Dana Point, California. Mr. Weiss' presentation is scheduled to take place on Tuesday, March 11, 2014 at 11:30 AM PT. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results and Business Update
GlobeNewswire - Wed Mar 05, 3:06PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced its financial results for the fourth quarter and year ended December 31, 2013 and provided recent company developments along with an outlook for 2014.
TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2013 Financial Results and Business Update
GlobeNewswire - Tue Mar 04, 7:31AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company, today announced that a conference call will be held on Thursday, March 6, 2014 at 8:30 a.m. ET to discuss results for the fourth quarter and year-end 2013, and provide a business outlook for 2014. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TG Therapeutics (TGTX) Worth Watching: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:25AM CST
TG Therapeutics was a big mover last session, with shares rising nearly 7%.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TG Therapeutics, Inc. to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Fri Feb 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual BIO CEO & Investor Conference being held at the Waldorf Astoria Hotel in New York City. Mr. Weiss' presentation is scheduled to take place on Monday, February 10, 2014 at 3:00 PM ET. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
Fc Protein and Glycoengineered Antibodies Market, 2013 - 2023 Report Presents Analysis and Insights
M2 - Fri Jan 31, 7:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/dvk3xp/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market, 2013 - 2023" report to their offering. The Fc Protein and Glycoengineered Antibody Market, 2013-2023 report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs and address several oncology specific diseases. With the market being fairly new, the report examines several elements of developing these next generation antibodies including technologies used for their production, site of engineering in an antibody and molecules in pipeline. For the purposes of this report, engineered antibodies are defined as antibodies which have been modified in their Fc region. The two types of modification considered are: - Fc Glycoengineering (referred to as Glycoengineering' in the report) - Fc Protein engineering The base year for the report is 2012, with estimated sales data presented for the single engineered antibody - Mogamulizumab - marketed so far. One of the primary objectives of this report is to understand the current and future status of the engineered antibody therapeutics market. This is done by analysing: - Molecules in pipeline and drugs approved for marketing across various markets - Research programs, focused on engineered antibody therapeutics, of global pharmaceutical companies and recently established start-ups - Technologies to produce engineered antibodies - Likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs The report provides short-mid term and long term market forecasts for the periods 2013 - 2018 and 2018 - 2023, respectively. Discussed, in detail, are the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the forecasted sales of - Seven marketed and pipeline glycoengineered antibodies and - Three pipeline Fc protein engineered antibodies Companies Mentioned: - ABN AMRO Capital - Amgen - Astra Zeneca - Boehringer Ingelheim - Bristol Myers Squibb - Deutsche Venture Capital - Dong-A Pharmaceutical - Eli Lilly - Five Prime Therapeutics - Genentech - Gilde Investment Management - GSK - Hanwha Chemical - Human Genome Sciences - ImmunGene - KaloBios - Life Science Pharmaceuticals - MacroGenics - Nippon Shinyaku - Novartis Venture Fund - Ortho-McNeil Janssen Pharmaceutical - Pfizer - Quester Capital Management - Regeneron Pharmaceuticals - Roche - Sanofi - Shanghai CP Guojian - Teva Pharmaceuticals - TG Therapeutics - Vivalis - Watson Pharmaceuticals - Xencor - Zymeworks For more information visit http://www.researchandmarkets.com/research/dv...rotein_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Biotech Stocks Under $10 to Watch
at The Street - Wed Jan 15, 6:00AM CST
Keep an eye on these biotech stocks under $10.
FDA Okays VIVO's Flu Assay, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 4:05PM CST
Meridian's Flu Assay gets the FDA approval
TG Therapeutics, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 13, 3:30PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 32 Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco. Mr. Weiss will discuss updates on the Company's two lead compounds for hematologic malignancies; TG-1101 (ublituximab) and TGR-1202. The presentation is scheduled to take place on Thursday, January 16, 2014 at 1:00 PM PST. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
NASA's Destination Station Exhibit Shares The Wonders Of The International Space Station
PR Newswire - Tue Jan 07, 1:41PM CST
OPENS JANUARY 24, 2014 AT THE CALIFORNIA SCIENCE CENTER
TG Therapeutics, Inc. Announces Presentation of Encouraging Clinical Activity of TGR-1202 in an Ongoing Multi-Center Phase I Clinical Study
GlobeNewswire - Mon Dec 09, 9:56AM CST
-- All evaluable CLL patients treated with once daily TGR-1202 at 800 mg exhibited significant nodal reductions with 3 of 4 patients achieving > 50% nodal partial response
TG Therapeutics, Inc. Launches Combination Clinical Trial of TG-1101 and Ibrutinib in Patients With Select B-Cell Malignancies
GlobeNewswire - Fri Dec 06, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that it has initiated a multi-center Phase 2 clinical trial to evaluate the safety and efficacy of the combination of TG-1101 (ublituximab) and ibrutinib (IMBRUVICA(R)) for patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). This will be the first clinical trial evaluating the combination of TG-1101, the Company's novel glycoengineered anti-CD20 monoclonal antibody, and ibrutinib, the oral Bruton Tyrosine Kinase (BTK) inhibitor which was recently granted approval by the U.S. Food and Drug Administration (FDA).
TG Therapeutics, Inc. Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting
GlobeNewswire - Thu Dec 05, 3:39PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that the following abstracts for TGR-1202, the Company's PI3K delta inhibitor, have been selected for poster presentation at the upcoming 55 Annual Meeting of the American Society of Hematology (ASH), to be held December 7 -10, 2013, at the Ernest N. Morial Convention Center, New Orleans, LA:
TG Therapeutics, Inc. to Present at the 2013 Deutsche Bank BioFEST Conference
GlobeNewswire - Tue Nov 26, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 2013 Deutsche Bank BioFEST Conference being held at the Four Seasons Hotel in Boston. Mr. Weiss' presentation is scheduled to take place on Tuesday December 3, 2013 at 4:35 PM ET. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
TG Therapeutics, Inc. Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL
GlobeNewswire - Mon Nov 25, 7:00AM CST
-- Combination trial led by Susan O'Brien, MD and Nathan Fowler, MD from the MD Anderson Cancer Center in Houston, Texas
TG Therapeutics, Inc. Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 6:50AM CST
TG Therapeutics, Inc. Enters Oversold Territory
TG Therapeutics, Inc. Announces Third Quarter 2013 Financial Results and Business Update
GlobeNewswire - Mon Nov 11, 3:30PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced its results for the third quarter ended September 30, 2013 and recent company developments.
TG Therapeutics to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013
ACCESSWIRE - Mon Nov 11, 8:31AM CST
NEW YORK, NY - (ACCESSWIRE - November 11, 2013) - TG Therapeutics, Inc. (TGTX) will host a live webcast to discuss the results of the third quarter 2013, to be held Tuesday, November 12, 2013 at 8:30 a.m. Eastern Time. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will be the main presenter for this event.
TG Therapeutics, Inc. Announces $18.1 Million Underwritten Sale of Common Stock to a Single Institutional Investor
GlobeNewswire - 1 hr 39 mins ago
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced it has priced an underwritten sale of 2,702,809 shares of its common stock at $6.71 per share, the closing price on March 11, 2014, to JP Morgan Asset Management's Global Healthcare Fund. Gross proceeds from the sale are expected to be approximately $18.1 million. TG Therapeutics intends to use the proceeds from the offering to fund the clinical development of TG-1101 and TGR-1202 and other general corporate purposes. The offering is expected to close on or about March 17, 2014, subject to customary closing conditions.
TG Therapeutics, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Mar 10, 9:01AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 26 Annual ROTH Conference being held at the Ritz Carlton Hotel in Dana Point, California. Mr. Weiss' presentation is scheduled to take place on Tuesday, March 11, 2014 at 11:30 AM PT. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results and Business Update
GlobeNewswire - Wed Mar 05, 3:06PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced its financial results for the fourth quarter and year ended December 31, 2013 and provided recent company developments along with an outlook for 2014.
TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2013 Financial Results and Business Update
GlobeNewswire - Tue Mar 04, 7:31AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company, today announced that a conference call will be held on Thursday, March 6, 2014 at 8:30 a.m. ET to discuss results for the fourth quarter and year-end 2013, and provide a business outlook for 2014. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TG Therapeutics (TGTX) Worth Watching: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:25AM CST
TG Therapeutics was a big mover last session, with shares rising nearly 7%.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TG Therapeutics, Inc. to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Fri Feb 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual BIO CEO & Investor Conference being held at the Waldorf Astoria Hotel in New York City. Mr. Weiss' presentation is scheduled to take place on Monday, February 10, 2014 at 3:00 PM ET. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
Fc Protein and Glycoengineered Antibodies Market, 2013 - 2023 Report Presents Analysis and Insights
M2 - Fri Jan 31, 7:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/dvk3xp/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market, 2013 - 2023" report to their offering. The Fc Protein and Glycoengineered Antibody Market, 2013-2023 report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs and address several oncology specific diseases. With the market being fairly new, the report examines several elements of developing these next generation antibodies including technologies used for their production, site of engineering in an antibody and molecules in pipeline. For the purposes of this report, engineered antibodies are defined as antibodies which have been modified in their Fc region. The two types of modification considered are: - Fc Glycoengineering (referred to as Glycoengineering' in the report) - Fc Protein engineering The base year for the report is 2012, with estimated sales data presented for the single engineered antibody - Mogamulizumab - marketed so far. One of the primary objectives of this report is to understand the current and future status of the engineered antibody therapeutics market. This is done by analysing: - Molecules in pipeline and drugs approved for marketing across various markets - Research programs, focused on engineered antibody therapeutics, of global pharmaceutical companies and recently established start-ups - Technologies to produce engineered antibodies - Likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs The report provides short-mid term and long term market forecasts for the periods 2013 - 2018 and 2018 - 2023, respectively. Discussed, in detail, are the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the forecasted sales of - Seven marketed and pipeline glycoengineered antibodies and - Three pipeline Fc protein engineered antibodies Companies Mentioned: - ABN AMRO Capital - Amgen - Astra Zeneca - Boehringer Ingelheim - Bristol Myers Squibb - Deutsche Venture Capital - Dong-A Pharmaceutical - Eli Lilly - Five Prime Therapeutics - Genentech - Gilde Investment Management - GSK - Hanwha Chemical - Human Genome Sciences - ImmunGene - KaloBios - Life Science Pharmaceuticals - MacroGenics - Nippon Shinyaku - Novartis Venture Fund - Ortho-McNeil Janssen Pharmaceutical - Pfizer - Quester Capital Management - Regeneron Pharmaceuticals - Roche - Sanofi - Shanghai CP Guojian - Teva Pharmaceuticals - TG Therapeutics - Vivalis - Watson Pharmaceuticals - Xencor - Zymeworks For more information visit http://www.researchandmarkets.com/research/dv...rotein_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Biotech Stocks Under $10 to Watch
at The Street - Wed Jan 15, 6:00AM CST
Keep an eye on these biotech stocks under $10.
FDA Okays VIVO's Flu Assay, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 4:05PM CST
Meridian's Flu Assay gets the FDA approval
TG Therapeutics, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 13, 3:30PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 32 Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco. Mr. Weiss will discuss updates on the Company's two lead compounds for hematologic malignancies; TG-1101 (ublituximab) and TGR-1202. The presentation is scheduled to take place on Thursday, January 16, 2014 at 1:00 PM PST. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
NASA's Destination Station Exhibit Shares The Wonders Of The International Space Station
PR Newswire - Tue Jan 07, 1:41PM CST
OPENS JANUARY 24, 2014 AT THE CALIFORNIA SCIENCE CENTER
TG Therapeutics, Inc. Announces Presentation of Encouraging Clinical Activity of TGR-1202 in an Ongoing Multi-Center Phase I Clinical Study
GlobeNewswire - Mon Dec 09, 9:56AM CST
-- All evaluable CLL patients treated with once daily TGR-1202 at 800 mg exhibited significant nodal reductions with 3 of 4 patients achieving > 50% nodal partial response
TG Therapeutics, Inc. Launches Combination Clinical Trial of TG-1101 and Ibrutinib in Patients With Select B-Cell Malignancies
GlobeNewswire - Fri Dec 06, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that it has initiated a multi-center Phase 2 clinical trial to evaluate the safety and efficacy of the combination of TG-1101 (ublituximab) and ibrutinib (IMBRUVICA(R)) for patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). This will be the first clinical trial evaluating the combination of TG-1101, the Company's novel glycoengineered anti-CD20 monoclonal antibody, and ibrutinib, the oral Bruton Tyrosine Kinase (BTK) inhibitor which was recently granted approval by the U.S. Food and Drug Administration (FDA).
TG Therapeutics, Inc. Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting
GlobeNewswire - Thu Dec 05, 3:39PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that the following abstracts for TGR-1202, the Company's PI3K delta inhibitor, have been selected for poster presentation at the upcoming 55 Annual Meeting of the American Society of Hematology (ASH), to be held December 7 -10, 2013, at the Ernest N. Morial Convention Center, New Orleans, LA:
TG Therapeutics, Inc. to Present at the 2013 Deutsche Bank BioFEST Conference
GlobeNewswire - Tue Nov 26, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 2013 Deutsche Bank BioFEST Conference being held at the Four Seasons Hotel in Boston. Mr. Weiss' presentation is scheduled to take place on Tuesday December 3, 2013 at 4:35 PM ET. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.
TG Therapeutics, Inc. Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL
GlobeNewswire - Mon Nov 25, 7:00AM CST
-- Combination trial led by Susan O'Brien, MD and Nathan Fowler, MD from the MD Anderson Cancer Center in Houston, Texas
TG Therapeutics, Inc. Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 6:50AM CST
TG Therapeutics, Inc. Enters Oversold Territory
TG Therapeutics, Inc. Announces Third Quarter 2013 Financial Results and Business Update
GlobeNewswire - Mon Nov 11, 3:30PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced its results for the third quarter ended September 30, 2013 and recent company developments.
TG Therapeutics to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013
ACCESSWIRE - Mon Nov 11, 8:31AM CST
NEW YORK, NY - (ACCESSWIRE - November 11, 2013) - TG Therapeutics, Inc. (TGTX) will host a live webcast to discuss the results of the third quarter 2013, to be held Tuesday, November 12, 2013 at 8:30 a.m. Eastern Time. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will be the main presenter for this event.
